S&P 500   3,320.55 (+1.51%)
DOW   26,731.70 (+0.80%)
QQQ   278.51 (+2.53%)
AAPL   116.48 (+4.75%)
MSFT   206.36 (+1.82%)
FB   282.03 (+5.36%)
GOOGL   1,578.16 (+4.46%)
AMZN   3,224.51 (+1.95%)
TSLA   414.40 (+2.06%)
NVDA   525.60 (+4.06%)
BABA   314.54 (+2.14%)
CGC   18.85 (+2.78%)
GE   7.38 (-0.54%)
MU   50.75 (+1.50%)
AMD   78.69 (+3.00%)
T   26.89 (+1.47%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.81 (+0.15%)
NFLX   506.19 (+4.10%)
NIO   31.90 (+15.96%)
BA   148.63 (+0.33%)
DIS   121.89 (+2.89%)
S&P 500   3,320.55 (+1.51%)
DOW   26,731.70 (+0.80%)
QQQ   278.51 (+2.53%)
AAPL   116.48 (+4.75%)
MSFT   206.36 (+1.82%)
FB   282.03 (+5.36%)
GOOGL   1,578.16 (+4.46%)
AMZN   3,224.51 (+1.95%)
TSLA   414.40 (+2.06%)
NVDA   525.60 (+4.06%)
BABA   314.54 (+2.14%)
CGC   18.85 (+2.78%)
GE   7.38 (-0.54%)
MU   50.75 (+1.50%)
AMD   78.69 (+3.00%)
T   26.89 (+1.47%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.81 (+0.15%)
NFLX   506.19 (+4.10%)
NIO   31.90 (+15.96%)
BA   148.63 (+0.33%)
DIS   121.89 (+2.89%)
S&P 500   3,320.55 (+1.51%)
DOW   26,731.70 (+0.80%)
QQQ   278.51 (+2.53%)
AAPL   116.48 (+4.75%)
MSFT   206.36 (+1.82%)
FB   282.03 (+5.36%)
GOOGL   1,578.16 (+4.46%)
AMZN   3,224.51 (+1.95%)
TSLA   414.40 (+2.06%)
NVDA   525.60 (+4.06%)
BABA   314.54 (+2.14%)
CGC   18.85 (+2.78%)
GE   7.38 (-0.54%)
MU   50.75 (+1.50%)
AMD   78.69 (+3.00%)
T   26.89 (+1.47%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.81 (+0.15%)
NFLX   506.19 (+4.10%)
NIO   31.90 (+15.96%)
BA   148.63 (+0.33%)
DIS   121.89 (+2.89%)
S&P 500   3,320.55 (+1.51%)
DOW   26,731.70 (+0.80%)
QQQ   278.51 (+2.53%)
AAPL   116.48 (+4.75%)
MSFT   206.36 (+1.82%)
FB   282.03 (+5.36%)
GOOGL   1,578.16 (+4.46%)
AMZN   3,224.51 (+1.95%)
TSLA   414.40 (+2.06%)
NVDA   525.60 (+4.06%)
BABA   314.54 (+2.14%)
CGC   18.85 (+2.78%)
GE   7.38 (-0.54%)
MU   50.75 (+1.50%)
AMD   78.69 (+3.00%)
T   26.89 (+1.47%)
F   7.95 (+3.25%)
ACB   4.00 (+4.44%)
GILD   58.81 (+0.15%)
NFLX   506.19 (+4.10%)
NIO   31.90 (+15.96%)
BA   148.63 (+0.33%)
DIS   121.89 (+2.89%)
Log in
NASDAQ:HUGE

FSD Pharma Stock Forecast, Price & News

$1.56
-0.02 (-1.27 %)
(As of 10/29/2020 12:57 PM ET)
Add
Compare
Today's Range
$1.56
Now: $1.56
$1.80
50-Day Range N/A
52-Week Range
$1.55
Now: $1.56
$14.00
Volume6,309 shs
Average Volume348,557 shs
Market Capitalization$20.25 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.25 out of 5 stars

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HUGE
CUSIPN/A
CIKN/A
Phone(416) 854-8884
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$190,000.00
Book Value$5.15 per share

Profitability

Net Income$-39,200,000.00

Miscellaneous

Market Cap$20.25 million
Next Earnings Date12/4/2020 (Estimated)
OptionableOptionable
$1.56
-0.02 (-1.27 %)
(As of 10/29/2020 12:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HUGE News and Ratings via Email

Sign-up to receive the latest news and ratings for HUGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











FSD Pharma (NASDAQ:HUGE) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of FSD Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FSD Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FSD Pharma
.

When is FSD Pharma's next earnings date?

FSD Pharma is scheduled to release its next quarterly earnings announcement on Friday, December 4th 2020.
View our earnings forecast for FSD Pharma
.

How were FSD Pharma's earnings last quarter?

FSD Pharma Inc. (NASDAQ:HUGE) announced its quarterly earnings data on Friday, August, 7th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.32.
View FSD Pharma's earnings history
.

Who are some of FSD Pharma's key competitors?

What other stocks do shareholders of FSD Pharma own?

Who are FSD Pharma's key executives?

FSD Pharma's management team includes the following people:
  • Raza Bokhari, Executive Co-Chairman & Chief Executive Officer
  • Zeeshan Saeed, President & Director
  • Donal Carroll, Chief Financial Officer
  • Sandra R. Lottes, VP & Head-Clinical Research BioSciences Division
  • Edward J. Brennan, President-BioSciences Division

What is FSD Pharma's stock symbol?

FSD Pharma trades on the NASDAQ under the ticker symbol "HUGE."

How do I buy shares of FSD Pharma?

Shares of HUGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is FSD Pharma's stock price today?

One share of HUGE stock can currently be purchased for approximately $1.56.

How big of a company is FSD Pharma?

FSD Pharma has a market capitalization of $20.25 million and generates $190,000.00 in revenue each year. The company earns $-39,200,000.00 in net income (profit) each year or ($5.55) on an earnings per share basis.

What is FSD Pharma's official website?

The official website for FSD Pharma is fsdpharma.com.

How can I contact FSD Pharma?

FSD Pharma's mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The company can be reached via phone at (416) 854-8884 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.